RESUMO
The polymorphism of cytokine genes (11-1beta, IL-10, IL-6, and TGF-beta1) in patients with chronic C hepatitis and in healthy individuals was studied. The study found that the polymorphism of IL-1beta, IL-6, and TGF-beta1 may at least partially explain the genetic predisposition to an aggressive course of the disease with the development of terminal stage.
Assuntos
DNA/genética , Hepatite C Crônica/genética , Interleucina-10/genética , Interleucina-1beta/genética , Interleucina-6/genética , Polimorfismo Genético , Fator de Crescimento Transformador beta1/genética , Adolescente , Adulto , Progressão da Doença , Feminino , Predisposição Genética para Doença , Hepatite C Crônica/sangue , Hepatite C Crônica/complicações , Humanos , Interleucina-10/sangue , Interleucina-1beta/sangue , Interleucina-6/sangue , Cirrose Hepática/etiologia , Cirrose Hepática/patologia , Masculino , Pessoa de Meia-Idade , Reação em Cadeia da Polimerase , Prognóstico , Índice de Gravidade de Doença , Fator de Crescimento Transformador beta1/sangueRESUMO
HBV and HCV markers were detected in the blood serum of patients with acute and chronic hepatitis B (HCV), chronic hepatis C (HCV), and acute nonA, non-B, non-C hepatitis by enzyme immunoassay and the polymerase chain reaction (PCR) in order to assess the clinical value of PCR for the diagnosis of HBV and HCV and monitor the antiviral roferon A therapy in patients with HCV. HBV DNA was detected by the PCR in 100% of acute HBV patients and in 65.7% of chronic HBV patients. In chronic HCV, the PCR detected HCV RNA in 71% of cases. After roferon A therapy, HCV RNA was no longer detected in 43.2% of PCR-positive patients. PCR is recommended for the diagnosis of acute and chronic HCV, selecting the patient groups, and assessing the efficacy of specific therapy.
Assuntos
Hepatite B/diagnóstico , Hepatite C/diagnóstico , Reação em Cadeia da Polimerase , Adulto , Antivirais/uso terapêutico , DNA Viral/análise , Feminino , Hepacivirus/genética , Anticorpos Anti-Hepatite B/análise , Antígenos do Núcleo do Vírus da Hepatite B/análise , Antígenos de Superfície da Hepatite B/análise , Vírus da Hepatite B/genética , Hepatite C/tratamento farmacológico , Humanos , Técnicas Imunoenzimáticas , Imunoglobulina M/análise , Interferon alfa-2 , Interferon-alfa/uso terapêutico , Masculino , Pessoa de Meia-Idade , RNA Viral/análise , Proteínas RecombinantesRESUMO
The epidemiological importance of prophylaxis of virus hepatitis B among medical personnel of therapeutic-preventive establishments is caused by often revealing of infecting markers in various groups of the population and patients and the chronization of infectious process, the peculiarities of complications, the outcomes of hepatitis and the character of ways of transfer of the virus. The authors have established non-uniformity of the frequency of revealing of infecting markers by virus hepatitis B in blood of medical personnel of various department of the hospital, have described results of immunological efficiency of the domestic vaccine hepatitis B, produced by firm "Kombitech Ltd." (Russia).